US FDA finalizes three biosimilars guidances
This article was originally published in SRA
The US Food and Drug Administration can knock three biosimilars guidances off its to-do list after finalizing the documents and giving industry more certainty on what's needed to submit so-called 351(k) applications to the agency and gain approval.
You may also be interested in...
With two new guidance documents, agency is trying to bring order to the potentially chaotic regulatory process that insulins and other currently approved protein products will face in March 2020; FDA also issues two more Q&A guidance documents on scientific and regulatory considerations for biosimilars.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.